AG
NKTR icon

Algert Global’s Nektar Therapeutics NKTR Stock Holding History

Algert Global’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.5M Buy
34,782
+19,472
+127% +$1.11M 0.04% 655
2025
Q4 		$647K Buy
+15,310
New +$857K 0.01% 914
2025
Q2 		– Sell
-3,247
Closed -$33K – 1292
2025
Q1 		$33K Buy
+3,247
New +$42.4K ﹤0.01% 1156
2024
Q2 		– Sell
-1,962
Closed -$27K – 1567
2024
Q1 		$27K Sell
1,962
-1,840
-48% -$19.3K ﹤0.01% 1045
2023
Q4 		$32K Sell
3,802
-8,240
-68% -$62.4K ﹤0.01% 1110
2023
Q3 		$108K Hold
12,042
– – 0.01% 1024
2023
Q2 		$104K Buy
+12,042
New +$128K ﹤0.01% 1032
2023
Q1 		– Sell
-23,174
Closed -$786K – 1253
2022
Q4 		$786K Sell
23,174
-8,587
-27% -$416K 0.04% 659
2022
Q3 		$1.52M Buy
31,761
+2,894
+10% +$172K 0.09% 370
2022
Q2 		$1.65M Buy
28,867
+24,000
+493% +$1.51M 0.12% 260
2022
Q1 		$394K Buy
+4,867
New +$720K 0.03% 887
2015
Q3 		– Sell
-1,455
Closed -$273K – 334
2015
Q2 		$273K Buy
+1,455
New +$250K 0.15% 232

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Algert Global's NKTR Position: Q1 2026 in Review

Algert Global increased its Nektar Therapeutics (NKTR) stake by 127% in Q1 2026, buying an estimated $1.11M and bringing the position to 34,782 shares worth $2.5M. The position accounts for 0.04% of the portfolio, ranked #655.

Algert Global first reported a position in NKTR in Q2 2015 and has held it in 12 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Algert Global held 34,782 shares of Nektar Therapeutics worth $2.5M as of Q1 2026.
  • Algert Global bought 19,472 Nektar Therapeutics shares in Q1 2026, an estimated $1.11M.
  • Nektar Therapeutics made up 0.04% of Algert Global's portfolio in Q1 2026, its #655 holding.
  • Algert Global first reported a position in Nektar Therapeutics in Q2 2015 and has held it in 12 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Algert Global's 13F filing for Q1 2026, filed 14 May 2026.